2H,3H,4H-pyrido[4,3-b][1,4]oxazine hydrochloride | 1354940-75-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2H,3H,4H-pyrido[4,3-b][1,4]oxazine hydrochloride
• 英文别名: 3,4-dihydro-2H-pyrido[4,3-b][1,4]oxazine;hydrochloride
• CAS: 1354940-75-2
• 化学式: C7H9ClN2O
• 分子量: 172.61
• InChiKey: LSTSYQROBHAOKP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.31
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  34.2
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• METHOD FOR PREPARING HETEROCYCLIC DERIVATIVE COMPOUND, COMPOSITION CONTAINING SAME COMPOUND, AND HYDRATE OF SAME COMPOUND
  申请人：JW Pharmaceutical Corporation

  公开号：EP3632917A1

  公开（公告）日：2020-04-08

  The present invention relates to: a novel method for preparing a heterocyclic derivative compound of chemical formula I below; a novel intermediate compound used in the preparation method; a composition for treatment or prevention of hyperuricacidemia, gout, nephritis, chronic renal insufficiency, nephrolith, uremia, urolithiasis, or a uric acid-related disease, the composition containing the compound of chemical formula I at a dose of more than 2 mg and equal to or less than 10 mg and being orally administered once a day; and a hydrochloride 1.5 hydrate of the novel compound of chemical formula I.

  本发明涉及一种用于制备下述化学式 I 的杂环衍生物化合物的新方法；一种用于该制备方法的新中间体化合物；一种用于治疗或预防高尿酸血症、痛风、肾炎、慢性肾功能不全、肾结石、尿毒症、尿石症或尿酸相关疾病的组合物，该组合物含有剂量大于 2 毫克且等于或小于 10 毫克的化学式 I 的化合物，每天口服给药一次；以及一种盐酸 1.5 水合物的化学式 I 的新型化合物。
• HYDROCHLORIDE SALT 1.5 HYDRATE OF AN HETEROCYCLIC DERIVATIVE COMPOUND
  申请人：JW Pharmaceutical Corporation

  公开号：EP3909956A1

  公开（公告）日：2021-11-17

  The present invention relates to: a novel method for preparing a heterocyclic derivative compound of chemical formula I below; a novel intermediate compound used in the preparation method; a composition for treatment or prevention of hyperuricacidemia, gout, nephritis, chronic renal insufficiency, nephrolith, uremia, urolithiasis, or a uric acid-related disease, the composition containing the compound of chemical formula I at a dose of more than 2 mg and equal to or less than 10 mg and being orally administered once a day; and a hydrochloride 1.5 hydrate of the novel compound of chemical formula I.

  本发明涉及一种用于制备下述化学式 I 的杂环衍生物化合物的新方法；一种用于该制备方法的新中间体化合物；一种用于治疗或预防高尿酸血症、痛风、肾炎、慢性肾功能不全、肾结石、尿毒症、尿石症或尿酸相关疾病的组合物，该组合物含有剂量大于 2 毫克且等于或小于 10 毫克的化学式 I 的化合物，每天口服给药一次；以及一种盐酸 1.5 水合物的化学式 I 的新型化合物。
• A PHARMACEUTICAL COMPOSITION COMPRISING A HETEROCYCLIC DERIVATIVE FOR USE IN THE TREATMENT OF HYPERURICEMIA
  申请人：JW Pharmaceutical Corporation

  公开号：EP3909955A1

  公开（公告）日：2021-11-17

  The present invention relates to: a novel method for preparing a heterocyclic derivative compound of chemical formula I below; a novel intermediate compound used in the preparation method; a composition for treatment or prevention of hyperuricacidemia, gout, nephritis, chronic renal insufficiency, nephrolith, uremia, urolithiasis, or a uric acid-related disease, the composition containing the compound of chemical formula I at a dose of more than 2 mg and equal to or less than 10 mg and being orally administered once a day; and a hydrochloride 1.5 hydrate of the novel compound of chemical formula I.

  本发明涉及一种用于制备下述化学式 I 的杂环衍生物化合物的新方法；一种用于该制备方法的新中间体化合物；一种用于治疗或预防高尿酸血症、痛风、肾炎、慢性肾功能不全、肾结石、尿毒症、尿石症或尿酸相关疾病的组合物，该组合物含有剂量大于 2 毫克且等于或小于 10 毫克的化学式 I 的化合物，每天口服给药一次；以及一种盐酸 1.5 水合物的化学式 I 的新型化合物。
• METHOD FOR PREPARING HETEROCYCLIC DERIVATIVE
  申请人：JW Pharmaceutical Corporation

  公开号：EP3632917B1

  公开（公告）日：2021-11-17
• Method For Preparing Heterocyclic Derivative Compound, Composition Containing Same Compound, And Hydrate of Same Compound
  申请人：JW PHARMACEUTICAL CORPORATION

  公开号：US20200207784A1

  公开（公告）日：2020-07-02

  The present invention relates to: a novel method for preparing a heterocyclic derivative compound of chemical formula I below; a novel intermediate compound used in the preparation method; a composition for treatment or prevention of hyperuricacidemia, gout, nephritis, chronic renal insufficiency, nephrolith, uremia, urolithiasis, or a uric acid-related disease, the composition containing the compound of chemical formula I at a dose of more than 2 mg and equal to or less than 10 mg and being orally administered once a day; and a hydrochloride 1.5 hydrate of the novel compound of chemical formula I.